Summary
34 / 100 · Bulios Score
What speaks for it
- Revenue grew by 31% a year over the last 3 years.
- Analysts expect revenue to grow by 32% this fiscal year.
What to watch
- The company made a loss over the last 12 months.
- Repaying its net debt would take 48.2 years of operating profit.
- The share price is above the Bulios Fair Price.
- It passes only 3 of the 9 points of the Piotroski financial health test.
Bulios Scoring describes a company's quality and track record, not its future return. A high score is not a buy signal. Learn more
Score in detailPrice
Is it expensive?
Looks expensiveBulios Fair Price is an estimate of a stock's fair value from the Bulios valuation model. It is an input for your own analysis, not investment advice. How does it work?
The company made a loss over the last 12 months, so there is no profit to set the price against.
Valuation in detailIs it growing?
Yes, fastRevenue (USD)
Diluted EPS (USD)
- Analyst estimate
Revenue grew by 38% a year over 5 years. Over the last 3 years it grew by 31% a year. For the next fiscal year analysts expect revenue to grow by 32%.
Growth in detailDoes it make money?
ReasonablyOver the last 12 months it made a loss of $206.3M.
Profitability in detailIs it financially healthy?
YesRepaying all its debt would take 9.3 years of free cash flow. It holds more cash than debt. The debt score is low because of the debt-to-equity ratio (2.2x).
Financial health in detailDoes it pay a dividend?
NoIt pays no dividend.
Dividends in detailWhat do analysts expect?
Mildly positive- Buy 29
- Hold 10
- Sell 2
Today's price within the analysts' price targets
The average target of $331.1 is 12% above today's price. 71% of the analysts recommend buying.
Analysts in detailWhat does it earn on?
Fiscal year 2025By product
- Reportable Segment 100%
By region
- UNITED STATES 49%
- EMEA 28%
- Asia Pacific 15%
- Other Geographical Regions 7.7%
Reportable Segment brings in 100% of revenue.
Segments in detail